These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 27483245)

  • 1. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
    Kawanami D; Matoba K; Sango K; Utsunomiya K
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
    Mora PF; Johnson EL
    Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.
    Mima A; Nomura A; Fujii T
    Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes.
    Farngren J; Ahrén B
    Metabolism; 2019 Oct; 99():25-31. PubMed ID: 31279738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
    Nauck MA; Meier JJ
    Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Incretin and incretin-based therapies].
    Harada N; Inagaki N
    Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F; Moretti A; Villa RF
    Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
    Bae EJ
    Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.
    Egger A; Kraenzlin ME; Meier C
    Curr Osteoporos Rep; 2016 Dec; 14(6):345-350. PubMed ID: 27709509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
    Davies MJ; Bianchi C; Del Prato S
    Metabolism; 2020 Jun; 107():154242. PubMed ID: 32315698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
    van Baar MJB; van Raalte DH
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.